Start-up Pre-Clinical Development and Diagnostics company with successful Series A round• Establishing budgets, cash runway, financial review of operations, preparing and presenting board materials• Evaluating lease options, capital equipment acquisition, in-house / outsource options, ramp-up• Supporting efforts to identify and expand new lines of business, monetization options

Emerging growth company leveraging Visual AI and Machine Learning in the medical device market• Implement and manage budgeting, forecasting and multi-year planning processes.• Evaluate and quantify sales contracts, service level agreements, including terms and pricing.• Collaborate on strategy for expanding product offerings including SaaS models and subscriptions.• Prepare board materials, analyze corporate development options (M&A, JV), equity fundraising activities with VCs.

SVP, Global Corporate Finance (9/2022 – 11/2023)VP of Corporate Finance / Business Development (10/2021 – 9/2022)Privately held, development-stage Global Biopharma enterprise evaluating, in-licensing, and developing innovative therapeutic products.• Established and managed new finance function, was responsible for budgeting, forecasting, analysis, strategic planning and business development support.• Modelled a comprehensive corporate planning and valuation file, provided critical insights for strategic decision-making and investment opportunities.• Collaborated with business development by providing financial expertise and guidance during term sheet negotiations, market sizing, and ROI calculations.• Managed a team of 10 finance professionals, including the Corporate Controller and Director of Finance.• Achieved cost savings of 10% of operating expenses, implemented efficient financial controls and vendor management process.• Successfully extended the cash flow runway by an additional 3 months through proactive cash management strategies.• Collaborated cross-functionally with Clinical, Business Development, Executive Team, and CEO, resulting in improved operating efficiency and cost controls.• Managed relationships and prepared in-depth analysis for banking and fundraising activities, as well as corporate partnership opportunities.• Communicated financial performance updates and insights to company stakeholders, board of directors, and investors, ensuring transparency and alignment.

VP, Corporate Finance - 1/2020 - 9/2021Senior Director of Finance - 1/2019 - 1/2020Director of Finance - 2/2017 - 12/2018Formerly Progenity, IncSpecialized Genetic Testing and Diagnostics• Hands on development and execution of corporate strategy, resulting in significant growth from a private / pre-IPO enterprise to public company status in June 2020.• Designed and executed department infrastructure to move from basic reporting to best-in-class business analytics and actionable management reporting, while keeping pace with the immediate needs of a highly complex and fast-moving organization.• Sourced and onboarded team from 3 analysts to 12 team members in both San Diego and Dallas locations to support corporate needs, focused on FP&A, Business Analytics, and Sales Support / Sales Analytics; Resulted in shortened decision cycles by executive team with more comprehensive information.• Created sophisticated and flexible financial models to facilitate detailed discussions between executive team, investors, and bankers. Ongoing projects included M&A opportunity review, SOX/Controls, ASC606 and Revenue Recognition, all corporate strategic projects, and commission / comp payouts. Extensive pre- and post-IPO analytics, worked closely with key external third parties in developing complex financial models.

Formerly New Century Health - Acquired• Built department infrastructure and analytic capability from scratch, including budgeting, forecasting, and reporting processes and deliverables. Reduced budget process by 4 months.• Hired and mentored both accounting and finance staff, successfully transitioned processes to existing staff, collaboratively worked with all departments to manage operating cash flow.• Met objectives at New Century Health to establish effective budgeting, forecasting, reporting, and analytical processes. With those objectives completed and the company poised to succeed, I transitioned from New Century Health to the San Diego area.

Director, Finance - 3/2015 – 4/2016Senior Manager, Finance - 6/2013 – 2/2015Formerly RainTree Oncology Services - Acquired• Prepared financial projections and analytics (including M&A and JV due diligence), valuations, data room management, due diligence (outside counsel, bankers, auditors) related to ~$100M sale of RainTree to Cardinal Healthcare.• Established and managed finance department processes, created advanced budgeting and forecasting models, monthly and quarterly operational reports, and financial dashboards. • Financial point person for the research, implementation, and growth of new sources of revenue. Revenue growth of 72% CAGR during tenure.• Worked with Executive Team on strategic projects, including securing external debt, HR planning, pharma compliance / contract support, and leveraging existing resources. Achieved 25% Opex efficiency.• Responsible for all corporate presentations to the BOD, external investors, and banking communities. Included summarizing business models, strategic plans, financial projections, and recommendations.

Associate Director, Finance - 1/2012 – 6/2013Manager, Finance - 1/2010 – 12/2011Senior Analyst - 11/2007 – 12/2009Formerly Actavis Pharmaceuticals - Merger• Calculated domestic sales allowances of more than $3.0 billion annually. Subsequent payment and balance sheet analysis consistently within 1% variance. Zero internal or external audit findings related to gross-to-net during tenure. • Wholly responsible for all net sales management, financial reporting, and contract compliance for the launch of key authorized generic product which generated over $150 million in gross profit. • Managed 20 separate domestic and international partner royalty agreements accounting for $585 million in annualized net revenue.• ASP flux for approximately 1,000 products, prepared product line profitability reports. Additional duties included SOX and internal audit controls testing, coordinating with external auditors.